CORT Corcept Therapeutics PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: CORT
- PE Ratio
As at Jul 3, 2025, the CORT stock has a price-to-earnings ratio of 56.91. This is based on the current EPS of $1.27 and the stock price of $72.27 per share. An increase of 21% has been recorded in the PE ratio compared to the average of 47.0 of the past four quarters.
CORT PE ratio history
The mean historical PE ratio of Corcept Therapeutics over the last ten years is 48.78. The current 56.91 price-to-earnings ratio is 17% more than the historical average. In the past ten years, CORT's PE ratio reached its highest point in the Jun 2016 quarter at 546, with a price of $5.46 and an EPS of $0.01. The Sep 2018 quarter saw the lowest point at 10.54, with a price of $14.02 and an EPS of $1.33.
Corcept Therapeutics PE ratio by year
Maximum annual increase: 92.62% in 2020
Maximum annual decrease: -84.73% in 2017
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 37.33 | 17.24% | $50.39 | $1.35 |
| 2023 | 31.84 | 48.92% | $32.48 | $1.02 |
| 2022 | 21.38 | 4.75% | $20.31 | $0.95 |
| 2021 | 20.41 | -28.21% | $19.8 | $0.97 |
| 2020 | 28.43 | 92.62% | $26.16 | $0.92 |
| 2019 | 14.76 | -28.18% | $12.1 | $0.82 |
| 2018 | 20.55 | 29.73% | $13.36 | $0.65 |
| 2017 | 15.84 | -84.73% | $18.06 | $1.14 |
| 2016 | 103.71 | N/A | $7.26 | $0.07 |
| 2015 | N/A | N/A | $4.98 | -$0.06 |
| 2014 | N/A | N/A | $3 | -$0.31 |
| 2013 | N/A | N/A | $3.21 | -$0.46 |
| 2012 | N/A | N/A | $1.43 | -$0.41 |
| 2011 | N/A | N/A | $3.42 | -$0.39 |
| 2010 | N/A | N/A | $3.86 | -$0.38 |
Corcept Therapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | 89.94 | 140.93% | $114.22 | $1.27 |
| Dec 2024 | 37.33 | 9.7% | $50.39 | $1.35 |
| Sep 2024 | 34.03 | 27.79% | $46.28 | $1.36 |
| Jun 2024 | 26.63 | 21.6% | $32.49 | $1.22 |
| Mar 2024 | 21.9 | -31.22% | $25.19 | $1.15 |
| Dec 2023 | 31.84 | 2.84% | $32.48 | $1.02 |
| Sep 2023 | 30.96 | 23.84% | $27.25 | $0.88 |
| Jun 2023 | 25 | 1.58% | $22.25 | $0.89 |
| Mar 2023 | 24.61 | 15.11% | $21.66 | $0.88 |
| Dec 2022 | 21.38 | -9.94% | $20.31 | $0.95 |
| Sep 2022 | 23.74 | 1.84% | $25.64 | $1.08 |
| Jun 2022 | 23.31 | 2.46% | $23.78 | $1.02 |
| Mar 2022 | 22.75 | 11.46% | $22.52 | $0.99 |
| Dec 2021 | 20.41 | -5.64% | $19.8 | $0.97 |
| Sep 2021 | 21.63 | -17.41% | $19.68 | $0.91 |
CORT Price vs fair value
CORT average PE ratio chart
The current PE ratio of CORT is above its 3, 5 and 10-year historical averages.
CORT PE vs peers
When compared to its peer LLY, CORT's PE ratio is lower, but it is higher than JNJ's and NVS's. Corcept Therapeutics's PE ratio is trading above the peer group average of 25.48.
| Stock name | PE ratio | Market cap |
|---|---|---|
| MRK Merck & Co Inc | 11.75 | $203.22B |
| JNJ Johnson & Johnson | 17.22 | $375.37B |
| BMY Bristol Myers Squibb Co | 17.51 | $95.49B |
| PFE Pfizer Inc | 18.26 | $144.29B |
| NVS Novartis AG | 18.93 | $238.84B |
| BMRN Biomarin Pharmaceutical Inc | 20.91 | $11.03B |
| MNKD Mannkind Corp | 36 | $1.09B |
| CORT Corcept Therapeutics Inc | 56.91 | $7.66B |
| LLY ELI LILLY & Co | 63.26 | $739.87B |
| ESPR Esperion Therapeutics Inc | N/A | $231.89M |
Frequently asked questions
What is Corcept Therapeutics's PE ratio?
The price to earnings ratio for CORT stock is 56.91 as of Jul 3, 2025.
What is the 3-year average PE ratio for Corcept Therapeutics (CORT)?
Over the last 3 years, the average PE ratio for CORT stock is 33.4.
What is the 5-year average PE ratio for Corcept Therapeutics (CORT)?
Over the last 5 years, the average PE ratio for CORT stock is 29.27.
What is the highest PE ratio for CORT?
In the last ten years, the Jun 2016 quarter recorded the highest quarterly PE ratio at 546.
How does the current PE ratio for CORT compare to its historical average?
CORT's current price to earnings ratio is 17% above its 10-year historical average.
How is CORT's PE ratio calculated (Corcept Therapeutics PE ratio formula)?
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (Jul 3, 2025), Corcept Therapeutics's stock price is $72.27. The earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $1.27. Therefore, Corcept Therapeutics's price to earnings ratio for today is 56.91. PE RATIO(56.91) = STOCK PRICE($72.27) / TTM EPS($1.27)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.